---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-053369"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:23:26.900802+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nektar Q1 net loss $44.9M; cash $731.6M; rezpegaldesleukin Phase 3 to start July

## Summary
- Net loss $44.9M ($1.82 loss per share) vs $50.9M in Q1 2025.
- Cash & investments $731.6M; excludes $351M net proceeds from April offering.
- R&D $35.7M, G&A $13.4M; total operating costs $49.9M.
- Phase 3 ZENITH-AD program in atopic dermatitis to initiate by July 2026.
- Closed public offerings raising $460M in Feb and $373.8M in April.

## SEC filing metadata
- accession: 0001213900-26-053369
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/0001213900-26-053369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/ea0289611-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-053369
- JSON: https://secwatch.observer/filing/0001213900-26-053369.json
- Plain text: https://secwatch.observer/filing/0001213900-26-053369.txt

## Source-grounded claims
- claim_id: 94d80f1b4ff3d2c97712d95b637bf806f6a532f3
  claim: NEKTAR THERAPEUTICS reported first quarter ended March 31, 2026 results: revenue 10.9 million, net income 44.9 million, EPS 1.82.
  evidence_excerpt: Revenue in the first quarter of 2026 was $10.9 million as compared to $10.5 million in the first quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/0001213900-26-053369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.